Company’s 36-month beta value is 1.09.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CNSP is 56.56M, and currently, short sellers hold a 2.01% ratio of that floaft. The average trading volume of CNSP on November 26, 2024 was 14.85M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CNSP) stock’s latest price update
Cns Pharmaceuticals Inc (NASDAQ: CNSP) has experienced a decline in its stock price by -7.56 compared to its previous closing price of 0.12. However, the company has seen a fall of -4.17% in its stock price over the last five trading days. accesswire.com reported 2024-11-25 that Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company’s novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population.
CNSP’s Market Performance
CNSP’s stock has fallen by -4.17% in the past week, with a monthly drop of -13.01% and a quarterly drop of -31.22%. The volatility ratio for the week is 16.76% while the volatility levels for the last 30 days are 15.04% for Cns Pharmaceuticals Inc The simple moving average for the last 20 days is -3.56% for CNSP’s stock, with a simple moving average of -98.01% for the last 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -10.16% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.90% of loss for the given period.
Volatility was left at 15.04%, however, over the last 30 days, the volatility rate increased by 16.76%, as shares sank -20.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.24% lower at present.
During the last 5 trading sessions, CNSP fell by -4.17%, which changed the moving average for the period of 200-days by -99.17% in comparison to the 20-day moving average, which settled at $0.1192. In addition, Cns Pharmaceuticals Inc saw -99.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNSP starting from Gumulka Jerzy, who purchase 33,333 shares at the price of $0.30 back on Feb 01 ’24. After this action, Gumulka Jerzy now owns 43,006 shares of Cns Pharmaceuticals Inc, valued at $10,000 using the latest closing price.
Evans Carl Anthony, the Director of Cns Pharmaceuticals Inc, purchase 33,333 shares at $0.30 during a trade that took place back on Feb 01 ’24, which means that Evans Carl Anthony is holding 33,458 shares at $10,000 based on the most recent closing price.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -2684.89 for the present operating margin
- 0.6 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -2681.03. The total capital return value is set at -5.1. Equity return is now at value -2116.75, with -350.34 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -454.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1052.64.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of -52.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
In a nutshell, Cns Pharmaceuticals Inc (CNSP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
